摘要
目的:探讨炔雌醇环丙孕酮联合枸橼酸氯米芬对多囊卵巢综合征单核细胞趋化蛋白-1(MCP-1)、抗苗勒管激素(AMH)水平的影响。方法:选择2018年9月至2019年9月我院收治的多囊卵巢综合征患者42例,根据盲抽法将其分为两组,各21例。对照组采用妈富隆联合枸橼酸氯米芬治疗,观察组采用炔雌醇环丙孕酮联合枸橼酸氯米芬治疗。比较两组患者临床疗效、血清MCP-1、AMH水平、不良反应发生率。结果:较对照组相比,观察组临床疗效总有效率较高,差异有统计学意义(P<0.05);治疗后,两组患者血清MCP-1、AMH水平均降低,且较对照组相比,观察组血清MCP-1、AMH水平较低,差异具有统计学意义(P<0.05);两组不良反应发生率对比,观察组较对照组低,差异具有统计学意义(P<0.05)。结论:炔雌醇环丙孕酮联合枸橼酸氯米芬治疗多囊卵巢综合症效果确切,可降低血清MCP-1、AMH水平,且安全性较高。
Objective:To investigate the effect of ethinylestradiol and cyproterone citrate combined with clomiphene citrate on monocyte chemoattractant protein-1(MCP-1)and anti Mullerian hormone(AMH)levels in polycystic ovary syndrome(PCOS).Methods:42 patients with PCOS admitted to our hospital from September 2018 to September 2019 were selected and divided into two groups according to the blind extraction method,21 in each group.The control group was treated with marvelon and clomiphene citrate,while the observation group was treated with ethinylestradiol and cycloproprenone and clomiphene citrate.The clinical effect,serum MCP-1,AMH level and the incidence of adverse reactions were compared between the two groups.Results:Compared with the control group,the total effective rate of the observation group was higher,the difference was statistically significant(P There was statistical significance(P<0.05)).Conclusion:Cyproterone ethinylestradiol combined with clomiphene citrate is effective in the treatment of PCOS.It can reduce the level of serum MCP-1 and AMH,and has high safety.
作者
张一帆
ZHANG Yi-fan(Pingdingshan Maternal and Child Health Hospital Department of Gynecology,Pingdingshan Henan 467000,China)
出处
《药品评价》
CAS
2020年第7期20-22,共3页
Drug Evaluation